Intellia Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Novartis Institutes for BioMedical Research, Inc. | — | Other | 79,245 | — | — | 5,652,903 | Mar 3, 2017 |
| Atlas Venture Associates IX, L.P. | — | Other | 700,000 | — | — | 3,729,788 | Mar 3, 2017 |
| BAKER JULIAN | — | Purchase | 20,469 | $18.00 | $368,442 | 85,906 | May 11, 2016 |
| Bermingham Nessan | President & CEO | C | 437,019 | — | — | 786,633 | May 11, 2016 |
| GORDON CARL L | — | C | 1,847,400 | — | — | 1,847,400 | May 11, 2016 |
| Caribou Therapeutics Holdco, LLC | — | C | 5,244,234 | — | — | 5,593,846 | May 11, 2016 |
| Haurwitz Rachel E. | — | C | 5,244,234 | — | — | 5,593,846 | May 11, 2016 |
| Novartis Institutes for BioMedical Research, Inc. | — | C | 1,724,240 | — | — | 4,803,241 | May 11, 2016 |
| Atlas Venture Associates IX, LLC | — | C | 862,120 | — | — | 3,937,148 | May 11, 2016 |
| FORMELA JEAN FRANCOIS | — | C | 2,463,201 | — | — | 3,075,028 | May 11, 2016 |
| Temasek Holdings (Private) Ltd | — | Purchase | 300,000 | $18.00 | $5,400,000 | 790,527 | May 11, 2016 |
| ISALY SAMUEL D | — | Purchase | 191,466 | $18.00 | $3,446,388 | 2,603,646 | May 11, 2016 |